1. Resveratrol Protects against Skin Inflammation through Inhibition of Mast Cell, Sphingosine Kinase-1, Stat3 and NF-κB p65 Signaling Activation in Mice.
- Author
-
Carlucci CD, Hui Y, Chumanevich AP, Robida PA, Fuseler JW, Sajish M, Nagarkatti P, Nagarkatti M, and Oskeritzian CA
- Subjects
- Animals, Humans, Mice, Chemokines metabolism, Inflammation drug therapy, Inflammation metabolism, Mast Cells metabolism, Resveratrol therapeutic use, Sphingosine, STAT3 Transcription Factor metabolism, Dermatitis, Atopic drug therapy, Dermatitis, Atopic metabolism, NF-kappa B metabolism
- Abstract
Inflammation is pathogenic to skin diseases, including atopic dermatitis (AD) and eczema. Treatment for AD remains mostly symptomatic with newer but costly options, tainted with adverse side effects. There is an unmet need for safe therapeutic and preventative strategies for AD. Resveratrol (R) is a natural compound known for its anti-inflammatory properties. However, animal and human R studies have yielded contrasting results. Mast cells (MCs) are innate immune skin-resident cells that initiate the development of inflammation and progression to overt disease. R's effects on MCs are also controversial. Using a human-like mouse model of AD development consisting of a single topical application of antigen ovalbumin (O) for 7 days, we previously established that the activation of MCs by a bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) initiated substantial skin remodeling compared to controls. Here, we show that daily R application normalized O-mediated epidermal thickening, ameliorated cell infiltration, and inhibited skin MC activation and chemokine expression. We unraveled R's multiple mechanisms of action, including decreased activation of the S1P-producing enzyme, sphingosine kinase 1 (SphK1), and of transcription factors Signal Transducer and Activator of Transcription 3 (Stat3) and NF-κBp65, involved in chemokine production. Thus, R may be poised for protection against MC-driven pathogenic skin inflammation.
- Published
- 2023
- Full Text
- View/download PDF